The aim of the GENDRIVAX (GENome-DRIVen Vaccine) scientific program is to develop novel prophylactic vaccines against invasive bacterial diseases caused by Salmonella and Neisseria.
GENDRIVAX is a collaboration between the Wellcome Trust Sanger Institute (WTSI), the Swiss Tropical and Public Health Institute (STPHI), the Kenya Medical Research Institute (KEMRI) and the Novartis Vaccines Institute for Global Health (NVGH).
These four partners bring together academic innovation with industrial expertise through joint training and exchange initiatives. Through its affiliation with NVGH, the project has access to an impressive array of high technology equipment and expertise. Of particular relevance is the proteomics facility that enables detailed analysis of proteins present in OMB and the FACS facility for analysing the binding of antibodies generated against OMB to the bacterial surface. Novartis Vaccines also provides the facilities required for daily operation including extensive computer facilities, library facilities, and the human resource facility with dedicated staff to facilitate exchange programs including obtaining visas, assistance with housing, language training and more.
|Location||Eastern Europe, Central Asia, East Asia and Pacific, North Africa and Middle East, Latin America and Caribbean|